---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-24-003866"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2024-11-29T23:59:59+00:00"
generated_at: "2026-05-29T13:12:56.862754+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics completes 1-for-9 reverse stock split, adjusts warrant terms

## Summary
- Reverse share split ratio 1-for-9 effective after market close on Nov 27, 2024; trading begins split-adjusted Nov 29, 2024.
- Authorized share capital remains $20,000, now 22,222,222 ordinary shares; par value increased from $0.0001 to $0.0009 per share.
- Each pre-split warrant now exercisable for 1/9th of a share at $103.50 per post-split share; no fractional shares (rounded up).
- Trading symbols unchanged: SLXN and SLXNW; new CUSIP for ordinary shares: G1281K 122.
- Fractional shares from warrant exercise rounded up to nearest whole number, requiring full exercise price payment.

## SEC filing metadata
- accession: 0001178913-24-003866
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2024-11-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/0001178913-24-003866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/zk2432408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-24-003866
- JSON: https://secwatch.observer/filing/0001178913-24-003866.json
- Plain text: https://secwatch.observer/filing/0001178913-24-003866.txt

## Key facts
- Governance Changes
  Silexion Therapeutics Corp: Adjusted the terms of outstanding warrants due to a 1-for-9 reverse share split, decreasing the number of shares issuable per warrant and proportionately increasing the exercise price (effective 2024-11-27).
  - Effective: 2024-11-27
  source text: The Company notified Warrant holders that the Company has made the following adjustments to its outstanding Warrants, effective after the close of trading on November 27, 2024, as to be reflected in the Warrants upon the open of trading on November 29, 2024: • The number of ordinary shares issuable upon the exercise of each pre-Reverse Share Split Warrant to purchase one ordinary share will decrease proportionately to the Reverse Share Split ratio, resulting in each such Warrant being exercisable for 1/9th of an ordinary share following the Reverse Share Split; and • The exercise price of each post-Reverse Share Split Warrant to purchase one whole post-Reverse Share Split ordinary share will be proportionately increased nine-fold (relative to a pre-Reverse Share Split Warrant to purchase one pre-Reverse Share Split ordinary share), to $103.50 per post-Reverse Share Split ordinary share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/0001178913-24-003866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.